Investors
Investors
Novadip is a clinical stage, pre-commercial company that has raised $88M in Series A/B + Non-Dilutive Funding to date, will be eligible for an FDA Priority Review Voucher and 9 patents covering products and technology.
Novadip is reimagining the standard of care for tissue regeneration with a single treatment cure. Founded in 2013, the team is leveraging its 3M3 tissue regeneration platform to fuel its lead development products that accelerate healing of large bone defects, bone non-union and spine fusion in a single treatment.
Corporate Presentation
Recent News
Events & Roadshows
Why Novadip?
Disruptive Product Platform
- Novel utilization of adipose cells for single treatment cures
- Potential to address unmet clinical needs in tissue repair and oncology
- Multi-billion-dollar market opportunity across three product classes
Strong Foundation
- Clinical outcomes in 50+ patients provide platform validation
- Patents across nine families; additional patents pending worldwide
- Established GMP production can be leveraged across platforms
Management Strength
- Passionate leadership supported by renowned scientific advisory board
- Demonstrated ability to raise capital in Series A/B rounds
- Secured eligibility for priority review voucher worth >$100M
Significant Investment Upside Potential
- Portfolio offers multiple partnering, licensing and acquisition opportunities
- Substantial non-dilutive funding provides leverage to secure new investment
Highlights
- Our Mission: Develop a new class of regenerative tissue products that accelerate healing of large bone defects, bone non-union and spine fusion in a single treatment
- Clinical stage with three therapeutic product classes
- 50+ procedures completed for bone reconstruction
- $88 million Series A/B and non-dilutive funding
- Nine patents covering products and technology
- One FDA Priority Review Voucher, upon potential approval of NVD-003
- Total addressable market of $13.5 billion
- GMP-certified manufacturing facility and supply chain platform can rapidly deliver stable autologous and allogeneic tissue repair products around the globe
- Our Mission: Develop a new class of regenerative tissue products that accelerate healing of large bone defects, bone non-union and spine fusion in a single treatment
- Clinical stage with three therapeutic product classes
- 50+ procedures completed for bone reconstruction
- $88 million Series A/B and non-dilutive funding
- Nine patents covering products and technology
- One FDA Priority Review Voucher, upon potential approval of NVD-003
- Total addressable market of $13.5 billion
- GMP-certified manufacturing facility and supply chain platform can rapidly deliver stable autologous and allogeneic tissue repair products around the globe
Shareholders
New Science Ventures
CRCP Lifescience Fund
SRIW Investment for Growth
VIVES Inter University Fund
Fund+ Impacting Life Sciences
New Science Ventures
CRCP Lifescience Fund
SRIW Investment for Growth
VIVES Inter University Fund
Fund+ Impacting Life Sciences
Contact Us
We’d love to discuss investment opportunities with Novadip. Reach out to our investor relations team today.
What’s New
Read media coverage on Novadip including insights from our executive leadership team.
Careers
We work together as one team and are committed to developing and delivering groundbreaking treatments for patients.
Pipeline
Learn about our pipeline of allogeneic and autologous cell-based therapy product candidates.
About Us
Our mission is to develop a new class of regenerative tissue products that accelerate healing in a single treatment.